GERDx: Endoscopic Full-Thickness Plication for GERD

GERDx is an endoscopic device used to treat GERD by creating full-thickness plications — folds that draw tissue together — at the gastroesophageal junction, aiming to build a valve mechanism similar to what's achieved surgically with a fundoplication, but through an endoscope rather than an operation.

It's safe — serious complications are uncommon. Whether it reliably works is genuinely less certain than for some other endoscopic options, and this page is written to be upfront about that rather than presenting GERDx as equivalent to ARMA. Here's the honest summary: in early studies, many patients reported feeling better in the months after the procedure. But when researchers ran a more rigorous test — comparing the real procedure against a fake (sham) one, without patients knowing which they'd had — there wasn't a clear difference in actual acid reflux between the two groups. And looking further out, more than half of patients in the longest follow-up study available had gone back on medication or needed surgery within about five years. None of this means GERDx never helps — but it means going in without assuming it's as reliable as some other options, and talking through the specifics with your gastroenterologist first. The section further down this page, ‘The evidence in more detail,’ explains exactly which studies these numbers come from.

Using a specialized endoscopic device, the physician creates a series of full-thickness folds in the tissue at the gastroesophageal junction, drawing the tissue together to recreate the anatomy and angle that normally helps prevent reflux — conceptually similar to what a surgeon achieves by wrapping part of the stomach around the esophagus during a fundoplication, but performed endoscopically.

• Confirmed GERD, diagnosed through endoscopy, manometry, and pH monitoring
• Patients who have discussed the evidence above with their gastroenterologist and understand the realistic likelihood of needing further treatment later
• Generally limited to patients with a hiatal hernia under 2cm, based on the eligibility criteria used in the available studies
• Patients for whom ARMA has been considered and discussed as a comparison point, given its more consistent evidence base

• Before: upper GI endoscopy, esophageal manometry, and pH monitoring to confirm the diagnosis and assess suitability
• During: performed under sedation; the device creates the full-thickness plications at the gastroesophageal junction
• After: a period of dietary modification while the treated tissue heals, along with continued or resumed reflux medication as needed
• Follow-up: symptom review and, where appropriate, repeat objective testing (pH monitoring) to confirm whether the procedure has actually reduced acid exposure, rather than relying on symptom reports alone

This section is for anyone who wants the specific research behind the summary above — it's not necessary reading to make a decision, but it's here for full transparency.

An early feasibility study of the device showed statistically significant improvement in quality-of-life scores and reflux-symptom scores at 3 months — but nearly 1 in 5 patients in that same study had already needed conversion to surgical fundoplication by that point due to persistent symptoms. A more rigorous test came from a sham-controlled randomized trial — patients were randomly assigned to either the real procedure or a sham (placebo) procedure, without knowing which they received, and led by a research team based in Hyderabad, published in a leading international gastroenterology journal. That trial did not find a significant difference in objective esophageal acid exposure between the real procedure and the sham, which raises real questions about how much of the symptom improvement seen in less rigorous studies reflects a true anatomical effect versus a placebo response. Longer-term data, following patients for a median of nearly 5 years, found that at least 55% were ultimately classified as treatment failures — 25% needed conversion to surgical fundoplication, and 40% needed to resume regular reflux medication.

GERDx addresses the mechanical failure at the gastroesophageal junction rather than suppressing acid, so it suits patients whose reflux is objectively proven but whose response to medication is incomplete. Our gastroenterologists confirm that with pH monitoring and manometry before offering it, and will say plainly when ARMA, TIF, or surgery is the better fit. To have your candidacy assessed, book a consultation.